Divi’s Labs Q2 Review — Motilal Oswal Retains 'Neutral' Despite Strong Performance

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

We broadly retain our FY26/FY27/FY28 estimates. We value Divi's Laboratories Ltd. at 55x 12 months forward earnings to arrive at our target price of Rs 6,925.

Divi's continues to strengthen its position as a reliable contract development manufacturing company for global pharma players, aided by-

1. differentiated skill sets such as peptide and contrast media manufacturing,

2. enhanced reliability for supply despite geopolitical turmoil, and

3. a built capacity that would cater to future requirements.

Further, it continues to focus on improving operating efficiency in manufacturing generics and adding new molecules in this segment.

However, the current valuation adequately factors in the earnings upside. Reiterate Neutral.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.